RTP Mobile Logo
Breakfast with the Investigators: Urothelial Bladder Cancer (Webinar Video Proceedings)
Released June 2022

Featuring perspectives from Drs Yohann Loriot, Elizabeth Plimack and Jonathan Rosenberg. Published June 30, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of urothelial bladder cancer.

    LEARNING OBJECTIVES

    • Consider available data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into current care.
    • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for high-risk muscle-invasive bladder cancer (MIBC), and consider the current role of this strategy.
    • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (UBC).
    • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy in the treatment of newly diagnosed metastatic UBC, and determine the current utility of these agents in clinical practice.
    • Recall pivotal clinical trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with these approaches would be appropriate.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
    • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for NMIBC, MIBC and metastatic UBC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component and short post-test, enables the participant to earn up 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO22Bladder/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Yohann Loriot, MD, PhD
    Deputy Chair, Early Drug Development (DITEP)
    Chair, GU Oncology Group
    Leader, Resistance to Innovative Drugs Program
    Molecular Predictors and New Targets in Oncology, INSERM U981
    Gustave Roussy
    Villejuif, France

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Astellas, Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck KgaA, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Celsius Therapeutics, Janssen Biotech Inc, Merck Sharp & Dohme LLC, Roche Laboratories Inc, Sanofi Genzyme.

    Elizabeth R Plimack, MD, MS
    Chief, Division of Genitourinary Medical Oncology
    Director, Genitourinary Clinical Research
    Professor, Medical Oncology
    Deputy Director, Fox Chase Cancer Center
    Temple Health
    Philadelphia, Pennsylvania

    Advisory Committee: Astellas, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc.

    Jonathan E Rosenberg, MD
    Chief, Genitourinary Medical Oncology Service
    Division of Solid Tumor Oncology
    Enno W Ercklentz Chair
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Astellas, Seagen Inc; Consulting Agreements: Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Lilly, Merck, Mirati Therapeutics, Pfizer Inc, QED Therapeutics, Seagen Inc, Tyra Biosciences; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Seagen Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc; Honorarium: EMD Serono Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: June 2022
    Expiration date: June 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):